ePrints

A Cancer-Research Campaign (Crc) Phase-Ii Trial of Cb10-277 Given by 24-Hour Infusion for Malignant-Melanoma

Lookup NU author(s): Professor Alan Calvert

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The dacarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m(-2) over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.

Publication metadata

Author(s): Bleehen NM, Calvert AH, Lee SM, Harper P, Kaye SB, Judson I, Brampton M

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 1994

Volume: 70

Issue: 4

Pages: 775-777

Print publication date: 01/10/1994

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

PubMed id: 7917939

Share